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studies. Results: We estimated the indirect cost of cancer due to disability in EU 
at the amount of 4223.2 million EUR. However partial disability account for approx. 
20-25% of this sum and reduces potential savings to the amount of 844.6–1055.8 
million EUR. Further correction, taking into account the efficacy of rehabilitation 
programs (up to 85%), reduces this savings to 717.9–897.4 million EUR. Considering 
the loss of productivity due to sickness absence and presenteeism measured in 
cancer survivors’ population (19.1% and 37.3% respectively) potential savings for EU 
economy due to return to work of cancer survivors with a disability are calculated 
at the amount of 364.2-455.2 million EUR. ConClusions: Indirect cost of cancer 
related disability can be reduced, but probably only to a small extent.
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objeCtives: European guidelines recommend colorectal cancer screening of 
average-risk population. Besides cancer, adenomas deserving surveillance through 
colonoscopy, are found. Our objective was to estimate the resources needed to 
undergo the recommended surveillance of adenomas found under a population-
based colorectal cancer screening program. Methods: A previous discrete-event 
simulation model representing a colorectal cancer screening program for a target 
population of women and men aged 50-69 was used. The underlying conceptual 
model was based on the European Guidelines for both the screening process and 
follow-up after adenoma removal. Resources needed according to findings of the 
colonoscopy at screening were the following: genetic tests for polyposis; high-
complexity colonoscopies for high-risk adenomas and polyposis, non-complex 
colonoscopies for intermediate-risk adenomas; visits with gastroenterologists for 
high-risk adenomas and polyposis and with general practitioners for intermediate-
risk adenomas. Parameters were estimated from the Colorectal Cancer Screening 
Program of Barcelona and follow-up colonoscopy results from the literature. A 
20-year horizon starting in 2015 was simulated. The model included population’s 
ageing. Results were rescaled to the population of the whole territory (1.7 million 
target population). Results: The predicted number of colonoscopies at screen-
ing was 19,275, 18,829 and 20,988 for years 2015, 2024 and 2034, respectively. The 
predicted numbers of non-complex and high-complexity colonoscopies were 9,887 
and 7,760 in 2024 and 14,362 and 9,099 in 2034, respectively. The expected num-
ber of gastroenterologist and general practitioner visits were 9,137 and 15,154 in 
2024 and 10,494 and 19,989 in 2034, respectively. The number of genetic tests was 
545 and 659 for years 2024 and 2034, respectively. ConClusions: Implementing 
a population-based colorectal cancer screening program represents an increased 
demand of resources for surveillance of intermediate and high-risk adenomas found 
under the program. Results of the simulation model will allow distributing the 
resources geographically and predicting future need when the screening program 
is extended to all the territory.
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objeCtives: This study assesses frequency of CINV events and resource utiliza-
tion in patients treated with AC for solid cancers Methods: The study evaluated 
a randomly selected cohort of patients from Inovalon’s MORE2Research Edition 
claims database that includes longitudinal data from US health plans. Patients 
who received AC regimens on first day of each cycle in first line of therapy during 
last six months of 2013 were included. Total CINV events and CINV related and 
total hospital/ER visits were captured for cycles of interest in first line and were 
analyzed using chi-square to determine statistical differences between patients 
on NK-1 regimens and non-NK-1 regimens. Results: The study cohort consisted 
of 353 patients, 97% female, 60% with Commercial insurance, and 95% with breast 
cancer, with mean age of 53.1 and Charlson comorbidity score of 6.0. NK-1 based 
CINV regimens were utilized in 73% of the patients in the first chemotherapy cycle. 
Rescue anti-emetics were used by 53% of patients on NK-1 regimens versus 60% 
of patients on non NK-1 regimens. Frequency of CINV events was 41% for NK-1 
versus 45% for the non NK-1 group. Frequency of CINV related ER visits was 5% 
in the NK-1 group versus 12% in the non NK-1 group, p= 0.03. CINV related hospi-
talizations were 3% in the NK-1 group versus 4% in the non-NK-1 group. Total ER 
visits were lower in the NK-1 group compared to the non NK-1 group, 12% versus 
19%; total hospitalizations were also lower in the NK-1 group compared to the non 
NK-1 group, 8% versus 13%. ConClusions: For patients on highly emetogenic 
AC based chemotherapy regimens, NK-1 treatments result in decreased rates of 
CINV events and resource utilization, with CINV related ER visits statistically lower. 
Further studies are warranted to determine if results are generalizable to other 
cancer regimens and diagnoses.
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gressing were 2 813 and 2 703 USD for Docetaxelum and Gefitinibum, respectively. 
Costs of 1 treatment course (21 days) of Pemetrexed were in 1,9 times higher than 
Gefitinibum. Therapy with Gefitinibum increase of life expectancy on 6 months and 
on 0,226 QALY in comparison with Pemetrexed. Costs of 1 month without progres-
sion for Gefitinib were in average 1,8 times less (2 699 and 5 016 USD for Gefitinib 
and Pemetrexed, respectively). Therapy with Gifinitib allows to decrease the direct 
medical costs on 19%. ConClusions: Therapy with Gifinitib as the second line 
therapy in patients with non-small cell lung cancer is effective from clinical and 
economical point of view.
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objeCtives: Reducing premature mortality is a crucial public health objective. A 
widely used measure of premature mortality is years of potential life lost before 
a given age (e.g. age 80). The aim of this study was to analyze the effect that phar-
maceutical innovation had on premature cancer mortality in Portugal during the 
period 2002-2010. Methods: The analysis was performed by using a difference-
in-differences research design based on longitudinal disease-level data, in order to 
investigate whether the diseases that had a larger increase in the number of new 
available drugs (i.e. more pharmaceutical innovation) had larger declines in years of 
potential life lost before age 80 in Portugal. Herein, we present the results specific for 
cancer disease. This methodology controls for the effects of macroeconomic trends 
and overall changes in the healthcare system. Official databases were used, such as 
the Eurostat for the premature mortality data. Results: Drugs registered during 
the period 1994-2002 reduced the number of years of potential life lost to cancer 
before age 80 in 2010 by 26,645. The estimates indicate that if no drugs had been 
registered during 1994-2002, premature mortality from cancer would have increased 
by about 9%. The 2010 expenditure on cancer drugs registered during 1994-2002 
in Portugal was € 148,670,718. Thus, the estimated cost per life-year before age 80 
gained from previous pharmaceutical innovation was € 5,580 (reduction in hospital 
costs due to the impact of pharmaceutical innovation on cancer morbidity were not 
accounted). ConClusions: These findings indicate that pharmaceutical innova-
tion contributed with a significant reduction in the premature mortality caused by 
cancer in Portugal. Moreover, the estimated cost per life-year is well below even the 
lowest estimates of the value of a life-year saved.
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objeCtives: Cancer is the second leading cause of death in Ireland accounting for 
approximately 30% of all deaths. Of these, almost a third arise in those of working 
age. As well as the public health burden, cancer also imposes economic costs on 
society in general and employers in particular. This study measured the productivity 
costs associated with cancer-related premature mortality from an employer’s per-
spective in Ireland. Methods: Data was abstracted on the average annual number 
of cancer deaths between the ages of 15 and 64 in Ireland during 2005-2009 by 5-year 
age group and sex from the World Health Organization Cancer Mortality Database. 
The friction cost approach was used to value all premature cancer deaths (and those 
for the ten most common cancer sites in males and females), over a defined friction 
period (base-case = 79 days), by gross gender- and age-specific wages, adjusted for 
labour market characteristics. In sensitivity analyses estimates were adjusted for 
‘multiplier effects’ associated with modern work practices and for changing labour 
market conditions. Results: The all-cancer premature mortality cost was € 14.3 mil-
lion in 2009. Costs were more than two-fold higher for males than females. Base-case 
estimates were sensitive to changes in labour markets conditions and decreased by 
42% following adjustment for increased unemployment levels (from 4.6% to 12.7%). 
Productivity costs were higher in settings with modern team-based working prac-
tices rising by almost 30% in the case of females (17% for males). ConClusions: 
Employers are becoming increasingly aware of the adverse economic effects of illness. 
Our results reveal the magnitude of productivity costs associated with cancer-related 
premature mortality from an employer’s perspective in Ireland. These results provide 
a sense of the types and magnitude of costs that are explicitly excluded from eco-
nomic evaluations that fail to encompass a broader social perspective.
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objeCtives: The number of cancer survivors is growing due to progression in diag-
nosis and treatment. Approximately half of cancer survivors are at working age, 
however many of them do not return to work. One of the reasons is a disability of 
cancer survivors. Although cancer related disability is usually more severe compared 
to disability due to other diseases, real-life data showed up to 85% of disabled cancer 
survivors may return to work after comprehensive rehabilitation programs. The aim 
of this study was to estimate potential savings to EU economy due to return to work 
of disabled cancer survivors. Methods: Data on indirect cost of a cancer related 
disability were calculated based on Luengo-Fernandez at al. study and our own esti-
mation of a contribution of disability to indirect cost related to morbidity. Disability 
structure i.e. percentage of a partially disabled cancer survivors, was adopted from 
Polish Social Insurance Institution data (we assumed that population with complete 
disability or inability for independent existence can’t return to work). Presenteeism 
and absenteeism in cancer survivors were adopted from our previously published 
